Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RevvityFRA:PKN +8.55%76 FCF Margin % is 24.87% as of Jun. 2026, which is 51% above its 10-year median of 16.46. GuruFocus rates FRA:PKN with a GF Score™ of 76/100 and a GF Value™ of €98.72 (Modestly Overvalued). The stock has 11 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Revvity ranks better than 87.75% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Revvity's Free Cash Flow for the
three
months ended in Jun. 2026 was €156 Mil. Revvity's Revenue for the
three
months ended in Jun. 2026 was €628 Mil. Therefore, Revvity's FCF Margin % for the quarter that ended in Jun. 2026 was 24.87%.
The historical rank and industry rank for Revvity's FCF Margin % or its related term are showing as below:
FRA:PKN'
s FCF Margin % Range Over the Past 10 Years
Min: 0.36 Med: 16.46 Max: 34.61
Current: 19.01
During the past 13 years, the highest FCF Margin % of Revvity was 34.61%. The lowest was 0.36%. And the median was 16.46%.
FRA:PKN's FCF Margin % is ranked better than 87.75% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.44
vs FRA:PKN: 19.01
The historical data trend for Revvity's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PKN vs CRL, ICLR, MEDP: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Revvity's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revvity FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Revvity's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revvity (FRA:PKN) has a FCF Margin % of 24.87% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Revvity and its competitors. This is 51% above median its historical median of 16.46. Over the past decade, Revvity's FCF Margin % has ranged from 0.36 to 34.61. According to the industry distribution chart, Revvity ranks #25 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 12.3%.
Is Revvity's FCF Margin % too high?
Revvity's current FCF Margin % of 24.87% is 51% above median its 10-year median of 16.46. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 34.61. The Medical Diagnostics & Research industry median FCF Margin % is 0.44. Revvity's value of 24.87% is 5552.3% above this industry median. Based on the distribution chart, Revvity ranks #25 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Revvity has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Revvity's FCF Margin % compare to CRL and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Revvity ranks #25 out of 204 companies for FCF Margin %. This places Revvity in the top 12% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 0.44. Revvity's value of 24.87% is 5552.3% above this benchmark. Historically, Revvity's own FCF Margin % has ranged from 0.36 to 34.61 over the past decade. While the company's 10-year median is 16.46 vs. the industry median of 0.44, Revvity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
The median FCF Margin % among Medical Diagnostics & Research companies is 0.44, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revvity's current FCF Margin % of 24.87% is 5552.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Revvity and its competitors. For the Medical Diagnostics & Research industry, the median FCF Margin % is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revvity's current FCF Margin % is 24.87%, which is 51% above median its own 10-year median of 16.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revvity stock overvalued right now?
Based on GuruFocus' analysis, Revvity (FRA:PKN) is currently considered Modestly Overvalued. The stock's GF Value™ is €98.72, compared to a current price of €114.90 — trading 16.4% above its estimated fair value. The current FCF Margin % is 24.87%, which is 51% above median its 10-year median of 16.46 and 5552.3% above the Medical Diagnostics & Research industry median of 0.44. Revvity's overall GF Score™ is 76/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Revvity (FRA:PKN), the current FCF Margin % is 24.87% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revvity (FRA:PKN) Overvalued in 2026?
Based on GuruFocus' analysis, Revvity stock appears to be overvalued.
The current stock price of €114.90 is trading 16.4% above its estimated GF Value™ of €98.72.
GuruFocus considers Revvity to be Modestly Overvalued.
Key valuation signals for FRA:PKN:
FCF Margin %: 24.87% (51% above median its 10-year median of 16.46)
GF Value™: €98.72 vs. price of €114.90 (16.4% above fair value)
Industry Position: 5552.3% above the Medical Diagnostics & Research median (#25 of 204)
No single metric tells the full story. See the FRA:PKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
76GF Score
Get the complete analysis for FRA:PKN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PKN has been successfully added to your 
